Raymond James analyst Ryan Deschner raised the firm’s price target on Liquidia (LQDA) to $29 from $27 and keeps a Strong Buy rating on the shares. The firm expects Yutrepia to be approved on May 24, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LQDA:
- Liquidia Corporation Awaits FDA Decision on YUTREPIA
- Favorable Court Decision and Market Potential Propel Liquidia Technologies’ Buy Rating
- Liquidia reports Q1 EPS (45c) vs. (40c) last year
- Liquidia Technologies Updates Audit Report for March 2025
- Liquidia price target raised to $36 from $34 at Scotiabank